It is well known that, at optimal dosage, BRAF inhibitors induce paradoxical proliferation in BRAFWT primary melanoma cells 32, and even at suboptimal dosage in some BRAFV600‐resistant melanoma cell lines, as it appears in reported experiments 6. This evidence concerns the gene BRAF and melanoma.